Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.49 |
| ▸ | LMNA | P02545 | 3/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 6/20 | 0.45 |
| ▸ | GAA | P10253 | 2/20 | 0.45 |
| ▸ | GFER | P55789 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.45 |
| ▸ | PRKDC | P78527 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | GPR35 | Q9HC97 | 2/20 | 0.44 |
| ▸ | TPMT | P51580 | 1/20 | 0.44 |
| ▸ | EGFR | P00533 | 2/20 | 0.43 |
| ▸ | GALR2 | O43603 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | SYK | P43405 | 1/20 | 0.43 |
| ▸ | VCP | P55072 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12584732 | 0.93 | ALDH1A1 (0.49) | ALDH1A1LMNAHPGDTDP1MAPT | |
| SCHEMBL1401369 | 0.87 | ALDH1A1 (0.53) | ALDH1A1LMNATDP1MAPTHTT | |
| SCHEMBL9024763 | 0.86 | ALDH1A1 (0.46) | ALDH1A1LMNAHPGDTDP1MAPT | |
| SCHEMBL4103613 | 0.85 | ALDH1A1 (0.48) | ALDH1A1LMNATDP1MAPTHTT | |
| SCHEMBL3294994 | 0.85 | ALDH1A1 (0.59) | ALDH1A1LMNATDP1MAPTHTT | |
| SCHEMBL2911207 | 0.83 | ALDH1A1 (0.50) | ALDH1A1LMNATDP1MAPTGAA | |
| SCHEMBL2944676 | 0.83 | ALDH1A1 (0.50) | ALDH1A1LMNATDP1MAPTKDM4E | |
| SCHEMBL31077653 | 0.83 | ALDH1A1 (0.50) | ALDH1A1LMNATDP1MAPTGAA | |
| SCHEMBL29738113 | 0.83 | ALDH1A1 (0.50) | ALDH1A1LMNATDP1MAPTKDM4E | |
| SCHEMBL13557413 | 0.81 | ALDH1A1 (0.51) | ALDH1A1LMNAHPGDTDP1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12522612-B2 | PDE4 inhibitors, pharmaceutical compositions, and therapeutic applications | BIOTHERYX INC. (US) | 2026-01-13 | — | — | US | disclosed |
| US-20250325673-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS INC (US) | 2025-10-23 | — | — | US | disclosed |
| EP-4613773-A2 | IRAK DEGRADERS AND USES THEREOF | Kymera Therapeutics, Inc. (US) | 2025-09-10 | — | — | EP | disclosed |
| EP-3731869-B1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS INC (US) | 2025-07-23 | — | — | EP | disclosed |
| US-20250000985-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2025-01-02 | — | — | US | disclosed |
| US-12168057-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2024-12-17 | — | — | US | disclosed |
| US-20230398223-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-12-14 | — | — | US | disclosed |
| US-11723980-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2023-08-15 | — | — | US | disclosed |
| US-20230106066-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-04-06 | — | — | US | disclosed |
| US-20230071529-A1 | PDE4 INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND THERAPEUTIC APPLICATIONS | BIOTHERYX, INC. (US) | 2023-03-09 | — | — | US | disclosed |
| EP-4073074-A1 | PDE4 INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND THERAPEUTIC APPLICATIONS | Biotheryx, Inc. (US) | 2022-10-19 | — | — | EP | disclosed |
| US-11318205-B1 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2022-05-03 | — | — | US | disclosed |
| WO-2021119571-A1 | PDE4 INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND THERAPEUTIC APPLICATIONS | BIOTHERYX, INC. (US) | 2021-06-17 | — | — | WO | disclosed |
| US-10874743-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2020-12-29 | — | — | US | disclosed |
| CN-112105385-A | IRAK degrading agents and uses thereof | 凯麦拉医疗公司 | 2020-12-18 | — | — | CN | disclosed |
| EP-3731869-A1 | IRAK DEGRADERS AND USES THEREOF | Kymera Therapeutics, Inc. (US) | 2020-11-04 | — | — | EP | disclosed |
| US-20190192668-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2019-06-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10874743-B2 | IRAK degraders and uses thereof | IRAK2, IRAK3, IRAK1 | ALDH1A1 2776/4885LMNA 1656/4885HPGD 3843/4885 |
| US-20230106066-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | ALDH1A1 2776/4885LMNA 1656/4885HPGD 3843/4885 |
| US-20250325673-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | ALDH1A1 2776/4885LMNA 1656/4885HPGD 3843/4885 |
| US-20250000985-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | ALDH1A1 2776/4885LMNA 1656/4885HPGD 3843/4885 |
| US-11723980-B2 | IRAK degraders and uses thereof | IRAK2, IRAK3, IRAK1 | ALDH1A1 2776/4885LMNA 1656/4885HPGD 3843/4885 |
| US-20230071529-A1 | PDE4 INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND THERAPEUTIC APPLICATIONS | PDE4A, PDE4B, PDE2A | ALDH1A1 482/4885LMNA 2450/4885HPGD 197/4885 |
| US-12168057-B2 | IRAK degraders and uses thereof | IRAK2, IRAK3, IRAK1 | ALDH1A1 2776/4885LMNA 1656/4885HPGD 3843/4885 |
| US-20230398223-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | ALDH1A1 2776/4885LMNA 1656/4885HPGD 3843/4885 |
| US-20190192668-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | ALDH1A1 2776/4885LMNA 1656/4885HPGD 3843/4885 |
| US-11318205-B1 | IRAK degraders and uses thereof | IRAK2, IRAK3, IRAK1 | ALDH1A1 2776/4885LMNA 1656/4885HPGD 3843/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.